Precision Medicine & Drug Development Tools for Biopharma

Our brain-in-a-dish platform and AI-driven drug response prediction technology empower biopharma partners to accelerate discovery, validate biomarkers, and advance clinical trials with greater confidence.

By combining mechanistic insights from patient-derived neurons with computational analytics, PharmaKaire enables actionable decision-making across the drug development lifecycle.

  • Diverse Biobank of Patient-Derived Neurons
  • Clinically Relevant Drug Response Profiles
  • Patient Stratification Strategies
  • Biomarkers & Companion Diagnostics
Request Collaboration

Optimizing Drug Discovery, Development & Commercialization

Through PharmaKaire, neuronal assay data is integrated across the full drug development pipeline. From early discovery to post-marketing, the platform provides end-to-end development collaboration to improve success rates, reduce costs, and enable differentiated market access strategies. By combining translational neuroscience with AI analytics, we help partners make confident, data-driven decisions at every stage.

Evidence-Based Prioritization

Compare candidate compounds, elucidate mechanisms of action, and refine development pathways with neuronal assays and AI-enabled analytics.

De-Risk Clinical Trials

Generate drug response profiles to guide patient enrichment and stratification strategies, improving trial outcomes and reducing attrition.

Differentiated Therapies

Support biomarker-driven approaches, companion diagnostics, and market access strategies, with validated neuronal and functional drug response data.

See All Use Cases
See All Use Cases

NeuroKaire Platform: PharmaKaire-Empowered

Supporting the full journey throughout the drug development life cycle

step 1
Target Discovery & Validation
  • Umbrella & Basket trials
  • Biomarker Strategy

Candidate Screening & Prioritization

Optimizing clinical trials

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore

‍
An arrow hitting a target with white background
A document having a microscope with white background

‍
step 2
Preclinical
  • Validated Human Neuronal Models
  • Mechanistic Insights & Differentiation

Mechanistic Drug Differentiation

Enable gated decisions

  • Comparing between multiple drug candidates/ marketed drugs
  • Similarities and differences can be ascertained on specific patient populations
  • Powered by proprietary biomarkers, algorithms, and bio-repository
Explore
step 3
Phase I
  • Risk Mitigation
  • Optimized Trial Design

Mechanistic Insight

Distinguishing responders & non-reponsder

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore

‍
A triangle having an exclamatory mark in center with white background
A microscope with white background

‍
step 4
Phase II/III
  • Biomarker Approach: Exploratory, Stratification, CDx Development
  • Regulatory Filing Support

Previous non-responders identified as responders to pipeline drugs

Non-responders to citalopram identified as responders to pipeline drug

  • Identify and target specific population that does not respond to current standard of care
  • Support pipeline drug or marketed drug move to first line for patient subset
Explore
step 5
Post-Marketing
  • Market Access Strategies
  • Drug Repurposing
  • Functional Response Characterization

Moving To First Line With Response Biomarkers

The combination of genotype with gene expression levels provides a response biomarker for a marketed 3rd line drug.

  • A newly approved drug with limited commercial success
  • Biomarker approach identified a population of high responders
  • Market access in various regions is supported by the data
  • Targeted patient population for high response to support commercial strategy
Explore

‍
Three Giant bars with white background

Genetika+ Platform: StemifAi

Supporting the full journey throughout the drug development life cycle

An arrow hitting a target with white background
step 1

Target Discovery & Validation

  • Umbrella & Basket trials
  • Biomarker Strategy

Mechanistic Drug Differentiation

Enable gated decisions

  • Comparing between multiple drug candidates/ marketed drugs
  • Similarities and differences can be ascertained on specific patient populations
  • Powered by proprietary biomarkers, algorithms, and bio-repository
Explore
A document having a microscope with white background
step 2

Preclinical

  • Validated Human Model
  • Mechanistic Insight & Differentiation

Mechanistic Insight

Distinguishing responders & non-reponsder

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore
A triangle having an exclamatory mark in center with white background
step 3

Phase I

  • Risk Mitigation
  • Optimize Design

Candidate Screening & Prioritization

Optimizing clinical trials

  • Differential expression between responders and non-responders
  • Genes with higher expression in responders enrich for neuronal ligand-receptor interactions
  • Gene module analysis shows a difference in a network involved in extracellular-matrix and collagen between responder and non-responders
Explore
A microscope with white background
step 4

Phase II/III

  • Biomarker Approach: Exploratory, Stratification, CDx
  • Regulatory Filing Data

Previous non-responders identified as responders to pipeline drugs

Non-responders to citalopram identified as responders to pipeline drug

  • Identify and target specific popoulation that does not respond to current standard of care
  • Support pipeline drug or marketed drug move to first line for patient subset
Explore
Three Giant bars with white background
step 5

Post-Marketing

  • Market Access
  • Repurposing
  • Differentiation

Moving To First Line With Response Biomarkers

The combination of genotype with gene expression levels provides a response biomarker for a marketed 3rd line drug.

  • A newly approved drug with limited commercial success
  • Biomarker approach identified a population of high responders
  • Market access in various region is supported by the data
  • Targeted patient population for high response to support commercial strategy
Explore

Partnerships

Through strategic collaborations with pharma, biotech, and academic research institutions, NeuroKaire helps bring innovative psychiatric and neurological treatments to patients faster.

By embedding precision medicine and predictive modeling into partner programs, we reduce attrition, accelerate clinical validation, and unlock differentiated market opportunities.

Share our vision for accelerating development and improving success rates.

Request Collaboration
Cheerful male person keeping a smile on his face while being satisfied with the result of the experiment.
View of a concentrated female microbiologist in protective goggles and gloves dropping a sample into a petri dish while carrying out scientific research.
Young woman in a white coat sitting at a table in front of a computer monitor, working on a computer in a laboratory.
Senior male researcher carrying out scientific research in a lab using a gas chromatograph. Shallow depth of field, color-toned image.
A female doctor looking inside of microscope.